22 December 2008: The shares in NorDiag ASA will be traded exclusive of subscription right as of today, December 22 2008. It is referred to announcement from the company December 19 2008.

Contact:
CFO Tone Kvåle              
Phone: +47 91519576

About NorDiag:
NorDiag is a biotechnology company developing, manufacturing and marketing automated solutions, instruments and tests, for diagnostic of infectious diseases and cancer. The company`s core competence is isolation of bacterial and human DNA from difficult clinical samples, and the company has established a solid market share in the Scandinavian market for sexually transmitted infections. The company has similar applications for Tuberculosis and MRSA. An application for respiratory pathogens is under development. NorDiag is also developing a test that shall contribute to early diagnosis of colorectal cancer. NorDiag was founded in 2003 and has its headquarters in Oslo - Norway. The company has offices and laboratories in Bergen - Norway, Stockholm - Sweden and West Chester (PA) - USA. The group has 39 employees. NorDiag is listed on Oslo Stock Exchange with the ticker NORD. For further information - www.nordiag.com.

Read the notice in Norwegian here